<DOC>
	<DOCNO>NCT00003311</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness different regimen combination chemotherapy treat patient newly diagnose mantle cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Newly Diagnosed Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate complete response rate duration response patient newly diagnose diffuse nodular mantle cell lymphoma blastic variant treat high-dose methotrexate cytarabine high-dose cyclophosphamide , dexamethasone , doxorubicin , vincristine ( HCVAD ) . OUTLINE : This multicenter study . Patients may receive either regimen A regimen A regimen B , depend upon response . - Regimen A : Patients receive methotrexate IV 24 hour day 1 . Cytarabine administer IV 2 hour every 12 hour day 2 3 . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) daily begin day 4 continue blood count recover . Treatment repeat every 21 day 8 course . - Regimen B : Patients receive cyclophosphamide IV 3 hour every 12 hour day 1-3 . Doxorubicin administer IV 24 hour day 4 5 . Vincristine administer IV 30 minute day 4 11 . Dexamethasone administer orally IV day 1-4 11-14 . G-CSF administer SC begin day 6 continue blood count recover . Treatment repeat every 21 day 7 course . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 21-45 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm previously untreated nodular diffuse mantle cell lymphoma blastic variant No CNS involvement Not candidate stem cell transplantation refuse one PATIENT CHARACTERISTICS : Age : 16 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,000/mm^3* Platelet count great 100,000/mm^3* NOTE : * Unless lymphoma involvement Hepatic : Bilirubin le 1.5 mg/dL ( unless lymphoma involvement ) Renal : Creatinine le 2.0 mg/dL ( unless lymphoma involvement ) Cardiovascular : Cardiac ejection fraction least 50 % ( patient age 40 ) Other : Must willing receive blood transfusion Not pregnant nursing Fertile patient must use effective contraception HIV negative No comorbid medical psychiatric illness would preclude treatment No prior concurrent malignancy poor prognosis ( le 90 % probability survival 5 year ) PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>